Clinical trials: Neoplasm, Oral
Lung Cancer, Non-squamous, Non-small Cell
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any systemic therapy including…
- Trial name
- NCT06151574
- Testing
- zongertinib, pembrolizumab, cisplatin
- Where
- 163 sites in United States, Argentina and 24 more
- Volunteers
- 428 people
- Sponsor
- Boehringer Ingelheim
Advanced Solid Malignancies
Absorption, Distribution, Metabolism and Excretion (ADME) Study of TKI258 in Patients With Advanced Solid Malignancies
This is a phase l study to examine Absorption, Distribution, Metabolism and Excretion of TKI258. There are 2 cohorts. Cohort 1 (4 patients) will receive single radio-labeled 500mg dose of TKI258 followed after 15 days by daily…
- Trial name
- NCT00669097
- Testing
- TKI258
- Where
- Netherlands
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumor
Study of TRX-920 for Patients With Advanced Solid Tumors
The study drug TRX-920 Oral Gel contains SN38, an active metabolite of Irinotecan (CPT-11), which is a widely prescribed anti-cancer drug that has been approved in many countries for the treatment of colorectal and pancreatic…
- Trial name
- NCT06143774
- Testing
- TRX-920 Oral Gel (10 mg and 30 mg)
- Where
- 3 sites in Taiwan
- Volunteers
- 30 people
- Sponsor
- TaiRx, Inc.
Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
The main purpose of this first in human study with CC-122 is to assess the safety and action of a new class of experimental drug (Pleiotropic Pathway Modulator) in patients with advanced tumors unresponsive to standard therapies…
- Conditions
- Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier, Glioblastoma
- Trial name
- NCT01421524
- Testing
- CC-122
- Where
- 39 sites in United States, Belgium and 3 more
- Volunteers
- 271 people
- Sponsor
- Celgene
Breast Cancer, Metastatic Breast Cancer
Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer
This is a first-in-human, open-label, Phase 1 study evaluating BBI-940, an investigational kinesin oral molecular degrader, administered as monotherapy or in combination with fulvestrant in adults with advanced or metastatic…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer
- Trial name
- KOMODO-1 (NCT07408089)
- Testing
- BBI-940, Fulvestrant
- Where
- 8 sites in United States
- Volunteers
- 8 people
- Sponsor
- Boundless Bio, Inc.
Neuroblastoma
Oral Liquid 13-cis-retinoic Acid (13-CRA)
An open label, randomised, multiple dose, cross-over relative bioavailability and pharmacokinetics trial of a novel oral liquid and capsule formulations of 13-CRA administered to patients from 0 months - < 21 years.
- Trial name
- My-CRA (NCT03291080)
- Testing
- Liquid 13-Cis Retinoic Acid, Extracted capsules 13-CRA
- Where
- 10 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Nova Laboratories Limited
Advanced ER-Positive HER2-Negative Breast Cancer
A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer
This study is randomized, open-label, parallel-group, multicentre Phase 2 study aimed to compare the efficacy and safety of oral AZD9833 versus intramuscular (IM) fulvestrant in women with advanced breast cancer.
- Trial name
- SERENA-2 (NCT04214288)
- Testing
- AZD9833, Fulvestrant
- Where
- 85 sites in United States, Belgium and 14 more
- Volunteers
- 240 people
- Sponsor
- AstraZeneca
Malignant Thymoma
Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy
The intent of the study is to assess the antitumor activity of PHA-848125AC in patients with recurrent or metastatic, unresectable malignant thymoma previously treated with multiple lines of chemotherapy.
- Trial name
- NCT01301391
- Testing
- Milciclib Maleate
- Where
- 3 sites in United States, Italy
- Volunteers
- 30 people
- Sponsor
- Tiziana Life Sciences LTD
Prostate Cancer
A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy Subjects
The study was designed to evaluate the pharmacokinetic effects of Rifampicin on HRS-5041 after oral administration of HRS-5041 tablets in healthy subjects.
- Trial name
- NCT07014488
- Testing
- HRS-5041 Tablets, Rifampicin Capsule
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Neoplasms
A Study of NM-3 Administered Orally in Patients With Advanced Solid Tumors.
A study for patients who have failed standard therapy. If there is no dose limiting toxicities the patients will receive further cycles of therapy if there is no evidence of disease progression.
- Trial name
- NCT00046696
- Testing
- NM-3
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Genzyme, a Sanofi Company
Cancer
Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentin™)
The purpose of this study is to determine whether food has any effect on a single dose of Cediranib (AZD2171, Recentin™)followed by an assessment of the safety and tolerability of fixed daily dosing in comparison to varying dose…
- Trial name
- NCT00306891
- Testing
- Cediranib, Cediranib 30 - 90 mg
- Where
- 4 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Pigmented Villonodular Synovitis, Giant Cell Tumors of the Tendon Sheath
Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)
This is a Phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug called pexidartinib for the treatment of certain tumors for which surgical removal could cause more harm than good.
- Conditions
- Pigmented Villonodular Synovitis, Giant Cell Tumors of the Tendon Sheath, Tenosynovial Giant Cell Tumor
- Trial name
- ENLIVEN (NCT02371369)
- Testing
- Pexidartinib
- Where
- 39 sites in United States, Australia and 10 more
- Volunteers
- 120 people
- Sponsor
- Daiichi Sankyo
Carcinoma, Non-Small-Cell Lung
Efficacy and Safety of Oral Treatment With BIBF 1120 ES in Advanced Non-small-cell Lung Cancer
The overall purpose of this phase II trial was to evaluate the efficacy of 250 mg BIBF 1120 twice daily (BID) versus 150 mg BIBF 1120 BID in patients with advanced non-small-cell lung cancer (NSCLC) who had failed at least one…
- Trial name
- NCT02182050
- Testing
- BIBF 1120 ES low dose, BIBF 1120 ES high dose
- Volunteers
- 73 people
- Sponsor
- Boehringer Ingelheim
Neoplasms
A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer Patients
The primary objective of this study is to determine the recommended phase II dose of AVE0005 in combination with S-1 in Japanese cancer patients.
- Trial name
- NCT00479076
- Testing
- aflibercept (AVE0005), S-1
- Where
- Japan
- Volunteers
- 22 people
- Sponsor
- Sanofi
Solid Tumours
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study.
- Trial name
- NCT06581432
- Testing
- Zongertinib
- Where
- 92 sites in United States, Australia and 14 more
- Volunteers
- 588 people
- Sponsor
- Boehringer Ingelheim
Infertility, Female, Polycystic Ovary Syndrome
Antioxidant Supplement Associated With Oral Probiotics in Patients With PCOS in IVF
The aim of the study is to study the effect of an antioxidant food supplement associated with probiotics on the oocyte quality response, oxidative stress and microbiota function in an in vitro fertilization cycle in patients with…
- Trial name
- NCT04670393
- Testing
- FertyBiotic Woman Plus
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Fertypharm
Breast Neoplasm, Pancreatic Neoplasm
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2
The purpose of this study is to investigate a safe dose of TAK-165, once daily (QD), in patients with HER2-tumor expression.
- Conditions
- Breast Neoplasm, Pancreatic Neoplasm, Lung Neoplasm, Ovarian Neoplasm
- Trial name
- NCT00034281
- Testing
- TAK-165
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Takeda
Advanced Solid Tumors, Breast Cancer Recurrent
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity…
- Conditions
- Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer, High-grade Serous Ovarian Carcinoma
- Trial name
- NCT06799065
- Testing
- ATX-295, ATX-295 and bevacizumab (or biosimilar)
- Where
- 11 sites in United States
- Volunteers
- 218 people
- Sponsor
- Accent Therapeutics
Carcinoma, Non-Small-Cell Lung Cancer
Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)
A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult Chinese patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy…
- Trial name
- NCT03240393
- Testing
- INC280
- Sponsor
- Novartis Pharmaceuticals
Skin Cancer, Cutaneous Tumor
Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for Malignant Cutaneous Tumors
- Conditions
- Skin Cancer, Cutaneous Tumor, Cutaneous Metastasis
- Trial name
- NCT04068155
- Testing
- DaRT- Diffusing Alpha-emitters Radiation Therapy
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- Alpha Tau Medical LTD.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.